Skip to main content
. 2020 Apr 29;10:515. doi: 10.3389/fonc.2020.00515

Table 1.

Different criteria for HPD.

Name Cancer types Applications Definition Criteria Advantages Disadvantages Reference (year)
RECIST Solid tumors Tumor therapeutics PD ≥20% increase in size More accurate assessments for treatment response than before HPD undefined (12) (2001)
RECIST 1.1 Solid tumors Tumor therapeutics PD ≥20% increase in the sum of diameters of target lesions (new lesions are also considered progression) Improvement in dimension assessments; newer imaging technologies; new lesions are considered HPD undefined (11) (2009)
irRECIST Solid tumors Antitumor immunotherapy irPD ≥25% increase in tumor burden, repeatable Specific for immunotherapy HPD undefined (13) (2009)
TGRR Solid tumors PD-1/PD-L1 inhibitors HPD TGRR ≥2 First introduced HPD definition Pre-ICI treatments details are necessary; reference period is limited (16) (2017)
TGKR R/M HNSCC PD-1/PD-L1 inhibitors HPD TGKR ≥2 Pseudoprogression and HPD can be distinguished; simpler calculation Pre-ICI treatments details are necessary (17) (2017)
Kato et al. criteria Multiple types of solid tumors Immunotherapy agents HPD TTF <2 months; 50% increase in tumor burden; >2-fold change in progression rate Less time for HPD recognition Clinical status changes are ignored (18) (2017)
Lo Russo et al. criteria Multiple types of solid tumors ICIs HPD, ≥3 criteria TTF <2 months; 50% increase in tumor lesions; ≥ 2 new lesions; spread of disease; clinical deterioration by ECOG Applicable for first-line treatment with ICIs Higher false positive (19) (2019)

PD, progressive disease; R/M HNSCC, recurrent/metastatic head and neck squamous cell carcinoma; TGKR, ratio of the rate of tumor growth on ICI treatment to that before ICI treatment.